Following a public comment period, the Federal Trade Commission has approved a final consent order regarding Pfizer Inc.’s recent acquisition of Wyeth, and responses to members of the public who provided comments. The final order settles charges that the transaction as proposed would have been anticompetitive in a number of markets for animal vaccines and pharmaceutical products, and is designed to resolve those competitive issues.
The FTC vote approving the final order was 2-0, with Commissioners Pamela Jones Harbour and William E. Kovacic recused. (FTC File No. 091-0053; the staff contact is Kari A. Wallace, Bureau of Competition, 202-326-3085. See press release dated October 14, 2009, at http://www.ftc.gov/opa/2009/10/pfizer.shtm.)
Copies of the documents mentioned in this release are available from the FTC’s Web site at http://www.ftc.gov and from the FTC’s Consumer Response Center, Room 130, 600 Pennsylvania Avenue, N.W., Washington, DC 20580. Call toll-free: 1-877-FTC-HELP.
WASHINGTON – Today, the U.S. Department of the Treasury (Treasury), as Chair of the Committee…
WASHINGTON—Today, the U.S. Department of the Treasury’s Community Development Financial Institutions Fund (CDFI Fund) and…
Washington – The findings from the annual survey of U.S. portfolio holdings of foreign securities…
WASHINGTON – The U.S. Department of the Treasury hosted a roundtable on October 30 with…
WASHINGTON – The United States and the People’s Republic of China held the sixth meeting…
WASHINGTON — Today, the Department of the Treasury’s Office of Foreign Assets Control (OFAC) sanctioned…